455 related articles for article (PubMed ID: 15363194)
21. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
22. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
Silverman MB; Roche PC; Kho RM; Keeney GL; Li H; Podratz KC
Gynecol Oncol; 2000 Apr; 77(1):1-7. PubMed ID: 10739683
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas.
Carneiro FP; Ramalho LN; Britto-Garcia S; Ribeiro-Silva A; Zucoloto S
Dis Colon Rectum; 2006 May; 49(5):588-94. PubMed ID: 16575619
[TBL] [Abstract][Full Text] [Related]
24. Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables.
Ozuysal S; Oztürk H; Bilgin T; Filiz G
Arch Gynecol Obstet; 2005 Feb; 271(2):123-6. PubMed ID: 14740230
[TBL] [Abstract][Full Text] [Related]
25. [A study on expression of tumor suppressor gene p53 in endometrial carcinoma].
Xue F; Jiao S; Zhao F
Zhonghua Fu Chan Ke Za Zhi; 1995 Nov; 30(11):647-50. PubMed ID: 8745486
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma.
Lazaris AC; Theodoropoulos GE; Anastassopoulos P; Nakopoulou L; Panoussopoulos D; Papadimitriou K
Histol Histopathol; 1995 Jul; 10(3):661-8. PubMed ID: 7579815
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt.
el-A Helal T; Khalifa A; Kamel AS
Anticancer Res; 2000; 20(3B):2145-50. PubMed ID: 10928168
[TBL] [Abstract][Full Text] [Related]
28. [Immunohistochemical study of PCNA, p53 gene product and c-erbB-2 gene product in endometrial carcinoma].
Miyazaki M
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Apr; 48(4):269-76. PubMed ID: 8936111
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
[TBL] [Abstract][Full Text] [Related]
30. [The relationship between angiogenesis and p53 overexpression in endometrioid adenocarcinoma].
Yao Y; Peng Z; Yin R
Zhonghua Fu Chan Ke Za Zhi; 1999 Nov; 34(11):667-9. PubMed ID: 11479949
[TBL] [Abstract][Full Text] [Related]
31. Expression profiles of p63, p53, survivin, and hTERT in skin tumors.
Park HR; Min SK; Cho HD; Kim KH; Shin HS; Park YE
J Cutan Pathol; 2004 Sep; 31(8):544-9. PubMed ID: 15268709
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance.
Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical study of microvessel density, CD44 (standard form), p53 protein and c-erbB2 in gallbladder carcinoma.
Kalekou H; Miliaras D
J Gastroenterol Hepatol; 2004 Jul; 19(7):812-8. PubMed ID: 15209630
[TBL] [Abstract][Full Text] [Related]
34. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma.
Li SF; Shiozawa T; Nakayama K; Nikaido T; Fujii S
Cancer; 1996 Jan; 77(2):321-9. PubMed ID: 8625241
[TBL] [Abstract][Full Text] [Related]
35. Comparative study of p63 and p53 expression in tissue microarrays of malignant melanomas.
Brinck U; Ruschenburg I; Di Como CJ; Buschmann N; Betke H; Stachura J; Cordon-Cardo C; Korabiowska M
Int J Mol Med; 2002 Dec; 10(6):707-11. PubMed ID: 12429996
[TBL] [Abstract][Full Text] [Related]
36. bcl-2 and p53 in endometrial adenocarcinoma.
Taskin M; Lallas TA; Barber HR; Shevchuk MM
Mod Pathol; 1997 Jul; 10(7):728-34. PubMed ID: 9237185
[TBL] [Abstract][Full Text] [Related]
37. [Comparative study of P 53, Bcl-2, and C-erbB-2 expression in low-grade papillary bladder tumors].
Ramos Soler D; Navarro Fos S; Villamón Fort R; Gil Salom M; Llombart Bosch A
Arch Esp Urol; 2003 Apr; 56(3):277-85. PubMed ID: 12768988
[TBL] [Abstract][Full Text] [Related]
38. Expression of c-erbB-2 oncogene and p53 tumor suppressor gene in benign and malignant breast tissue: correlation with proliferative activity and prognostic index.
Alexiev BA; Bassarova AV; Popovska SL; Popov AA; Christov CZ
Gen Diagn Pathol; 1997 Jun; 142(5-6):271-9. PubMed ID: 9228249
[TBL] [Abstract][Full Text] [Related]
39. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder.
Koga F; Kawakami S; Fujii Y; Saito K; Ohtsuka Y; Iwai A; Ando N; Takizawa T; Kageyama Y; Kihara K
Clin Cancer Res; 2003 Nov; 9(15):5501-7. PubMed ID: 14654529
[TBL] [Abstract][Full Text] [Related]
40. Fluorescence in situ hybridization and immunohistochemical analysis of p53 expression in endometrial cancer: prognostic value and relation to ploidy.
Graesslin O; Chantot-Bastaraud S; Lorenzato M; Birembaut P; Quéreux C; Daraï E
Ann Surg Oncol; 2008 Feb; 15(2):484-92. PubMed ID: 18071824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]